Azorg
- Address
- Moorselbaan 164, 9300 Aalst, Belgium
Cardiovascular Diseases at Azorg
Clinical research in cardiology focuses on major cardiovascular diseases such as atrial fibrillation, atherosclerotic cardiovascular disease, and heart failure. These studies are designed to assess new treatment options, improve prevention of serious events, and support better long-term outcomes for people living with heart-related conditions.
- Testing a new approach to prevent stroke and other embolic complications in atrial fibrillation
- Evaluating therapies for heart failure with preserved or mildly reduced ejection fraction in people with obesity
- Assessing long-term safety and tolerability for patients with established cardiovascular disease and elevated Lp(a)
This work reflects a strong focus on both treatment effectiveness and prevention in common and high-risk cardiovascular conditions.
Neoplasms
The site also supports oncology research across neoplasms, with studies in breast cancer and prostate cancer. These trials aim to refine treatment strategies, reduce the chance of recurrence, and explore more personalized care guided by modern diagnostic tools.
- Improving recurrence prevention in ER+/HER2- early breast cancer through endocrine-based treatment research
- Studying treatment intensification and de-intensification options for high-risk prostate cancer
- Using advanced imaging and molecular tracers to better guide prostate cancer management
At Azorg, the oncology program combines therapeutic research with better disease targeting and quality-of-life considerations for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 93 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 86 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1Boehringer Ingelheim Espana S.A.3active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG5trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azorg
lock Showing 1 of 35 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM). | Kardigan Inc. | Phase IV | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 93 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 3 | Unknown | 2024-11-21 | 2025-11-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.